Meridian Bioscience Inc.

Find Ratings Reports
VIVO : NASDAQ : Health Technology
$14.4 -0.1 | -0.69%
Today's Range: 14.35 - 14.6
Avg. Daily Volume: 302900.0
02/20/18 - 3:41 PM ET

Financial Analysis


MERIDIAN BIOSCIENCE INC's gross profit margin for the first quarter of its fiscal year 2018 has decreased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago.

At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 4.31% from the same quarter last year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY18 Q1 FY17
Net Sales ($mil)52.2846.81
EBITDA ($mil)0.012.13
EBIT ($mil)9.5410.09
Net Income ($mil)6.36.28


Balance Sheet Q1 FY18 Q1 FY17
Cash & Equiv. ($mil)0.049.28
Total Assets ($mil)251.95250.06
Total Debt ($mil)53.5357.62
Equity ($mil)172.88165.73


Profitability Q1 FY18 Q1 FY17
Gross Profit Margin60.867.29
EBITDA Margin0.025.91
Operating Margin18.2521.55
Sales Turnover0.820.78
Return on Assets8.5611.84
Return on Equity12.4817.86
Debt Q1 FY18 Q1 FY17
Current Ratio0.05.99
Debt/Capital0.240.26
Interest Expense0.00.42
Interest Coverage0.023.84


Share Data Q1 FY18 Q1 FY17
Shares outstanding (mil)42.2142.2
Div / share0.130.2
EPS0.150.15
Book value / share4.13.93
Institutional Own % n/a n/a
Avg Daily Volume309032.0219639.0

Valuation


HOLD. This stock's P/E ratio indicates a significant discount compared to an average of 106.37 for the Health Care Equipment & Supplies industry and a premium compared to the S&P 500 average of 25.51. To use another comparison, its price-to-book ratio of 3.55 indicates valuation on par with the S&P 500 average of 3.26 and a significant discount versus the industry average of 5.71. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, MERIDIAN BIOSCIENCE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
VIVO 28.53 Peers 106.37   VIVO NA Peers 51.45

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

VIVO is trading at a significant discount to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
VIVO 19.14 Peers 26.79   VIVO 0.77 Peers 0.85

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

VIVO is trading at a discount to its peers.

 

Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

VIVO trades at a valuation on par to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
VIVO 3.55 Peers 5.71   VIVO -27.15 Peers -2.55

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

VIVO is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, VIVO is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
VIVO 2.98 Peers 5.74   VIVO 5.37 Peers 16.53

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

VIVO is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

VIVO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades